Home
/
Oruka Therapeutics, Inc.
/
Financials
/
Quarterly
Oruka Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Oruka Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2024
Jun 30, 2024
$0
Aug 1, 2024
Q1
2024
Mar 31, 2024
$0
Apr 25, 2024
Q3
2023
Sep 30, 2023
$0
Oct 18, 2023
Q1
2023
Jun 30, 2023
$0
Jul 21, 2023
Q1
2023
Mar 31, 2023
$0
Apr 24, 2023
Q3
2022
Sep 30, 2022
$0
Oct 28, 2022
Q2
2022
Jun 30, 2022
$0
Aug 2, 2022
Q1
2022
Mar 31, 2022
$0
May 2, 2022
Q3
2021
Sep 30, 2021
$0
Nov 2, 2021
Q2
2021
Jun 30, 2021
$0
Aug 4, 2021
Q1
2021
Mar 31, 2021
$0
May 11, 2021
Q3
2020
Sep 30, 2020
$0
Nov 2, 2020
Q2
2020
Jun 30, 2020
$0
Aug 5, 2020
Q1
2020
Mar 31, 2020
$0
May 6, 2020
Q3
2019
Sep 30, 2019
$0
Nov 6, 2019
Q2
2019
Jun 30, 2019
$0
Aug 1, 2019
Q1
2019
Mar 31, 2019
$0
May 8, 2019
Q3
2018
Sep 30, 2018
$0
Nov 14, 2018
Q2
2018
Jun 30, 2018
$0
Aug 9, 2018
Q1
2018
Mar 31, 2018
$0
May 8, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($30.28M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($24.57M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($21.00M)
May 14, 2025
Q3
2025
Sep 30, 2024
($28.62M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($22.24M)
Aug 11, 2025
Q3
2024
Jun 30, 2024
($22.24M)
Nov 13, 2024
Q2
2024
Mar 31, 2024
($2.01M)
Aug 1, 2024
Q1
2025
Mar 31, 2024
($7.08M)
May 14, 2025
Q3
2024
Mar 31, 2024
($7.08M)
Nov 13, 2024
Q1
2024
Dec 31, 2023
($1.09M)
Apr 25, 2024
Q2
2024
Dec 31, 2023
($1.09M)
Aug 1, 2024
Q3
2023
Sep 30, 2023
($1.42M)
Oct 18, 2023
Q1
2024
Sep 30, 2023
($1.42M)
Apr 25, 2024
Q2
2024
Sep 30, 2023
($1.42M)
Aug 1, 2024
Q3
2023
Jun 30, 2023
($1.48M)
Oct 18, 2023
Q1
2024
Jun 30, 2023
($1.48M)
Apr 25, 2024
Q2
2024
Jun 30, 2023
($1.48M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($1.35M)
Apr 25, 2024
Q2
2024
Mar 31, 2023
($1.35M)
Aug 1, 2024
Q3
2023
Mar 31, 2023
($1.35M)
Oct 18, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($34.11M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($28.43M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($25.09M)
May 14, 2025
Q3
2025
Sep 30, 2024
($29.45M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($21.49M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($6.86M)
May 14, 2025
Q3
2023
Sep 30, 2023
($1.94M)
Oct 18, 2023
Q2
2024
Jun 30, 2023
($1.97M)
Aug 1, 2024
Q1
2023
Jun 30, 2023
($1.97M)
Jul 21, 2023
Q1
2024
Mar 31, 2023
($1.80M)
Apr 25, 2024
Q3
2023
Sep 30, 2022
($2.55M)
Oct 18, 2023
Q2
2022
Jun 30, 2022
($3.22M)
Aug 2, 2022
Q1
2023
Jun 30, 2022
($3.22M)
Jul 21, 2023
Q1
2023
Mar 31, 2022
($3.28M)
Apr 24, 2023
Q3
2022
Sep 30, 2021
($4.72M)
Oct 28, 2022
Q2
2022
Jun 30, 2021
($4.84M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
($4.10M)
May 2, 2022
Q3
2021
Sep 30, 2020
($1.99M)
Nov 2, 2021
Q2
2021
Jun 30, 2020
($1.31M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($1.34M)
May 11, 2021